Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. The company was founded by Chad Robins, Harlan Robins, and Chris Carlson on September 8, 2009 and is headquartered in Seattle, WA.
相关临床试验
8
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
已完成
4
50.0%
招募中
1
12.5%
终止
2
25.0%
撤回
1
12.5%
暂无批准数据
- NCCN's updated multiple myeloma guidelines (version 1.2027) add a dedicated page, MYEL-E, consolidating Principles of MRD Testing for a more consistent clinical approach. - The guidelines set 10-6 as the preferred MRD sensitivity and 10-5 as the minimum, citing the higher prognostic value of deeper assessment. - clonoSEQ is the only assay specifically named in the guidelines as an FDA-cleared NGS test for bone marrow-based MRD assessment. - Recommended MRD timepoints now extend to annual testing during maintenance and after later lines of therapy, including CAR T-cell therapy.
- The OpenAI Foundation launched Public Data for Health, an effort to pay for high-quality scientific datasets it says AI needs to make medical breakthroughs. - A $500,000 grant to 1Day Sooner will fund bids at bankruptcy proceedings to acquire common technical documents from failed biotech companies. - The foundation also pledged $40 million for novel cancer vaccine data collection at the University of North Carolina, Chapel Hill, and support for OpenAdmet. - Separately, Harell Data raised $15 million to pay data generators a share of revenue from AI model builders using their curated datasets.
- Telo Genomics announced positive interim results from a retrospective clinical study evaluating its 3D telomere profiling platform in 50 multiple myeloma patients with known two-year outcomes. - The assay achieved an AUC of 0.849 in ROC analysis, with "Average Distance to Nuclear Center" emerging as the strongest predictor of relapse status. - The blood-based platform aims to combine MRD detection, malignant cell identification, and relapse-risk prognostication within a single liquid biopsy assay. - The company is also conducting parallel validation studies with Cleveland Clinic and Montreal Jewish General Hospital, comparing its platform against Adaptive Biotechnologies' ClonoSEQ®.
- Chief People Officer Francis Lo sold 39,741 shares of Adaptive Biotechnologies on June 4, 2026, for approximately $695,000 at a weighted average price of $17.49 per share. - The transaction was part of a pre-arranged Rule 10b5-1 trading plan adopted in September 2025, indicating a non-discretionary, routine liquidity move. - Lo retains substantial equity exposure with 250,934 direct shares, 2,500 indirect shares, and 483,489 stock options following the sale. - Adaptive Biotechnologies reported Q1 revenue of $70.9 million, a 35% year-over-year increase, reflecting strong company performance.
- Adaptive Biotechnologies announced two licensing agreements with Pfizer to leverage its T-cell receptor discovery platform for rheumatoid arthritis research and AI-driven drug development. - The partnership includes identifying disease-causing TCRs in rheumatoid arthritis patients and licensing Adaptive's proprietary TCR-antigen datasets for multiple immunology applications. - Adaptive could receive up to $890 million in potential milestones under the rheumatoid arthritis agreement, with Pfizer responsible for all development and commercialization activities. - The collaboration utilizes Adaptive's AI-enabled immune medicine platform and what the company believes is the largest publicly available TCR-antigen binding dataset.
- Adaptive Biotechnologies announced that its clonoSEQ MRD test will be featured in 89 abstracts at the 67th ASH Annual Meeting, including 36 oral presentations. - The abstracts span multiple blood cancers including multiple myeloma, acute lymphoblastic leukemia, chronic lymphocytic leukemia, mantle cell lymphoma, and diffuse large B-cell lymphoma. - More than 17 presentations demonstrate how clonoSEQ MRD assessment is informing patient treatment decisions in real-world clinical practice across various blood cancers. - The test continues expanding its use in clinical trials to assess treatment responses for novel therapies including CAR-T, bispecific antibodies, and other targeted treatments.
- Adaptive Biotechnologies and Flatiron Health have integrated the FDA-cleared clonoSEQ test for minimal residual disease assessment into OncoEMR, providing over 4,500 clinicians across 1,000 community cancer care locations streamlined access to MRD testing. - The integration enables providers to order and review clonoSEQ results directly within the electronic medical record, improving testing workflows and providing real-time insights into blood cancer patients' disease status. - clonoSEQ is the first and only FDA-cleared diagnostic test for detecting MRD in multiple myeloma, B-cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia, with sensitivity to detect one cancer cell in one million healthy cells. - The collaboration aims to enhance personalized treatment decisions in community oncology practices, where the majority of Americans receive their cancer care, by providing vital MRD data that serves as one of the strongest predictors of outcomes in blood cancer patients.
- Adaptive Biotechnologies has launched an upgraded clonoSEQ assay for DLBCL that delivers a 7-fold increase in sensitivity while maintaining high specificity for detecting minimal residual disease. - The enhanced assay has received approval from New York State's Clinical Lab Evaluation Program and aligns with updated NCCN guidelines recommending ctDNA testing for MRD assessment in DLBCL patients. - As the only DLBCL MRD test available for clinical use with Medicare coverage, clonoSEQ has been used to manage over 2,800 DLBCL patients, helping clinicians differentiate between likely cure and impending relapse.
- Adaptive Biotechnologies reported 42% growth in its Minimal Residual Disease (MRD) business for 2024, with clonoSEQ test volume increasing 35% to 76,105 tests delivered throughout the year. - The company secured a 17% increase in Medicare reimbursement rates for clonoSEQ tests and expanded Medicare coverage to include Mantle Cell Lymphoma, enabling new promotional efforts. - Despite overall revenue growth of 5% to $179 million in 2024, Adaptive reduced its net loss to $159.6 million from $225.3 million in 2023, with a focus on achieving MRD profitability in 2025.
- Data from the ECOG-ACRIN EA4151 trial suggests auto-HCT may not benefit MCL patients in first complete remission with undetectable MRD. - FELIX study data indicates deep molecular remission correlates with improved outcomes in relapsed/refractory B-ALL patients treated with obecabtagene autoleucel. - A Phase 3 trial showed that adding blinatumomab to chemotherapy significantly improves disease-free survival in pediatric B-ALL patients. - A Phase 2 study found that CLL patients achieving undetectable MRD after nine cycles of venetoclax and obinutuzumab can discontinue therapy early.
